Factors Associated with Mpox Vaccination Uptake Among Women of Transgender Experience and Transfeminine People in New York City, 2024.

Women of transgender experience (WTE) have been disproportionately burdened by mpox. Using 2024 data from the New York City site of the National HIV Behavioral Surveillance study among WTE and transfeminine people (TFP), we identified factors associated with receiving at least one dose of the mpox vaccine. Of 103 WTE/TFP, most identified as Hispanic/Latina and being born outside of the United States with 40% receiving at least one dose. Participants who self-reported having HIV were more than twice as likely to have received a dose (PR: 2.31; 95% CI: 1.20-4.47). Mpox vaccine outreach efforts may benefit from status-neutral strategies.